These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19230916)

  • 1. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer.
    Mononen N; Schleutker J
    J Urol; 2009 Apr; 181(4):1541-9. PubMed ID: 19230916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene polymorphisms and prostate cancer: the evidence.
    Dianat SS; Margreiter M; Eckersberger E; Finkelstein J; Kuehas F; Herwig R; Ayati M; Lepor H; Djavan B
    BJU Int; 2009 Dec; 104(11):1560-72. PubMed ID: 20053187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in androgen signaling pathway predisposing to prostate cancer.
    Schleutker J
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):25-37. PubMed ID: 21782882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgens and the molecular epidemiology of prostate cancer.
    Chu LW; Reichardt JK; Hsing AW
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):261-70. PubMed ID: 18438175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
    Lindström S; Zheng SL; Wiklund F; Jonsson BA; Adami HO; Bälter KA; Brookes AJ; Sun J; Chang BL; Liu W; Li G; Isaacs WB; Adolfsson J; Grönberg H; Xu J
    Prostate; 2006 Dec; 66(16):1729-43. PubMed ID: 16998812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of Afro-Caribbean population with prostate cancer].
    Veronique-Baudin J; Dieye M; Kouyoumdjian JC; Vacheron F; Draganescu C; Azaloux H
    Prog Urol; 2006 Jun; 16(3):303-10. PubMed ID: 16821341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.
    Singh AS; Chau CH; Price DK; Figg WD
    Nat Clin Pract Urol; 2005 Feb; 2(2):101-7. PubMed ID: 16474655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of molecular genetics in chemoprevention studies of prostate cancer.
    Ross RK
    IARC Sci Publ; 2001; 154():207-13. PubMed ID: 11220660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.
    Shaik AP; Jamil K; Das P
    Urol J; 2009; 6(2):78-86. PubMed ID: 19472123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort.
    Kesarwani P; Mandhani A; Mittal RD
    J Urol; 2009 Dec; 182(6):2938-43. PubMed ID: 19846139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.
    Lillie EO; Bernstein L; Ursin G
    Breast Cancer Res; 2003; 5(3):164-73. PubMed ID: 12793900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complex genetic epidemiology of prostate cancer.
    Schaid DJ
    Hum Mol Genet; 2004 Apr; 13 Spec No 1():R103-21. PubMed ID: 14749351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer.
    Koivisto PA; Hyytinen ER; Matikainen M; Tammela TL; Ikonen T; Schleutker J
    J Urol; 2004 Jan; 171(1):431-3. PubMed ID: 14665948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility.
    Teixeira AL; Ribeiro R; Morais A; Lobo F; Fraga A; Pina F; Calais-da-Silva FM; Calais-da-Silva FE; Medeiros R
    Pharmacogenomics J; 2009 Oct; 9(5):341-6. PubMed ID: 19488063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic biomarkers, androgen pathway and prostate cancer.
    D'Amico F; Biancolella M; Margiotti K; Reichardt JK; Novelli G
    Pharmacogenomics; 2007 Jun; 8(6):645-61. PubMed ID: 17559353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.